Key Takeaways
- • Blackstone funds will pay up to $1.5 billion of development costs for Pfizer's berobenatide through 2028, according to a Business Wire release dated November 11, 2026.
- • Blackstone's return is milestone-based, tied to U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management and to certain commercial sales milestones.
- • Blackstone acquires no rights or ownership in berobenatide, and Pfizer retains full operational control and decision-making over the program.
- • Berobenatide is an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide; Pfizer plans 10 ongoing and planned Phase 3 trials for it.
- • BXPE, Blackstone's perpetual private equity strategy, will invest alongside Blackstone Life Sciences funds in the transaction.
Summary
Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of $1.5 billion of development costs through 2028 for berobenatide. The drug is described by the companies as an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions.
In exchange for the funding, Blackstone will be eligible to receive milestone-based payments. These are subject to U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management, and to the achievement of certain commercial sales milestones. Any milestone payments, if earned, will be paid to Blackstone over a multi-year period. Under the agreement, Blackstone does not acquire any rights or ownership in the drug, and Pfizer retains full operational control and decision-making authority over the berobenatide program.
Funds managed by Blackstone's perpetual private equity strategy, BXPE, will invest alongside funds managed by Blackstone Life Sciences as part of the transaction. Blackstone Life Sciences, which the release says has $18 billion in assets under management, describes itself as an investment platform spanning the life cycle of life science companies and products.
Pfizer CFO and Executive Vice President Cecile Guegan said the arrangement helps the company advance its comprehensive obesity program while maintaining the financial capacity and flexibility to invest across its broader pipeline. She described the approach as pairing internal research investment with targeted investment from capital partners. Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences, said the deal positions berobenatide as the anchor of Pfizer's cardiometabolic pipeline and cited the firm's capacity to provide capital at scale.
Pfizer plans to advance more than 20 trials for obesity and related comorbidities in 2026. Berobenatide is being studied for obesity-related conditions including knee osteoarthritis and obstructive sleep apnea, both as a monotherapy and in combination with other Nutrient-Stimulated Hormone (NuSH) peptides, including amylin analogs. The release contains forward-looking statements and notes risks including clinical, regulatory and the ability to realize the anticipated benefits of the funding agreement.
In exchange for the funding, Blackstone will be eligible to receive milestone-based payments. These are subject to U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management, and to the achievement of certain commercial sales milestones. Any milestone payments, if earned, will be paid to Blackstone over a multi-year period. Under the agreement, Blackstone does not acquire any rights or ownership in the drug, and Pfizer retains full operational control and decision-making authority over the berobenatide program.
Funds managed by Blackstone's perpetual private equity strategy, BXPE, will invest alongside funds managed by Blackstone Life Sciences as part of the transaction. Blackstone Life Sciences, which the release says has $18 billion in assets under management, describes itself as an investment platform spanning the life cycle of life science companies and products.
Pfizer CFO and Executive Vice President Cecile Guegan said the arrangement helps the company advance its comprehensive obesity program while maintaining the financial capacity and flexibility to invest across its broader pipeline. She described the approach as pairing internal research investment with targeted investment from capital partners. Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences, said the deal positions berobenatide as the anchor of Pfizer's cardiometabolic pipeline and cited the firm's capacity to provide capital at scale.
Pfizer plans to advance more than 20 trials for obesity and related comorbidities in 2026. Berobenatide is being studied for obesity-related conditions including knee osteoarthritis and obstructive sleep apnea, both as a monotherapy and in combination with other Nutrient-Stimulated Hormone (NuSH) peptides, including amylin analogs. The release contains forward-looking statements and notes risks including clinical, regulatory and the ability to realize the anticipated benefits of the funding agreement.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.